{"@id":"https://bioecon.ru/technology/upar-targeted-senolytic-car-t-therapy/","@type":"Technology","cluster":"regenerative-personalized","formats":{"html":"https://cn.bioecon.ru/technology/upar-targeted-senolytic-car-t-therapy/","json":"https://cn.bioecon.ru/api/v1/technology/upar-targeted-senolytic-car-t-therapy/index.json"},"id":"upar-targeted-senolytic-car-t-therapy","industries":["advanced-therapies","longevity"],"lang":"cn","links":{"industries":["https://bioecon.ru/industries/advanced-therapies/","https://bioecon.ru/industries/longevity/"],"suppliers":["https://bioecon.ru/companies/cellmeat/","https://bioecon.ru/companies/agc-biologics/","https://bioecon.ru/companies/simple-planet/","https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/integriculture/","https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/newlimit/","https://bioecon.ru/companies/cryoport-systems/","https://bioecon.ru/companies/esco-aster/","https://bioecon.ru/companies/becton-dickinson/","https://bioecon.ru/companies/eversyn-gmbh/","https://bioecon.ru/companies/bionet/"]},"maturity":5,"name":"靶向uPAR清除衰老细胞与纤维化病灶的抗衰老CAR-T细胞疗法","regions":["us","eu","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-15","entity":"pmc.ncbi.nlm.nih.gov","kind":"research","urls":["https://pmc.ncbi.nlm.nih.gov/articles/PMC7583560/"]},{"date":"2026-11-15","entity":"www.nature.com","kind":"research","urls":["https://www.nature.com/articles/s41392-020-00268-7"]},{"date":"2026-11-15","entity":"memorial-sloan-kettering-spinouts","kind":"vendor","urls":[]},{"date":"2026-11-15","entity":"cold-spring-harbor-labs","kind":"vendor","urls":[]}],"stages":[{"n":1,"title":"靶向人源uPAR单链抗体合成"},{"n":2,"title":"慢病毒转导重编程自体T细胞"},{"n":3,"title":"体外低分化干性表型扩增"},{"n":4,"title":"单次低剂量静脉靶向输注治疗"}],"summary":"靶向衰老细胞广谱膜表面标志物尿激酶型纤溶酶原激活物受体 (uPAR) 的工程化CAR-T细胞。单次低剂量输注即可选择性诱发衰老成纤维细胞凋亡，逆转肝脏及肺部纤维化，修复组织再生微环境。","url":"/technology/upar-targeted-senolytic-car-t-therapy/","verified":"2026-11-15"}